Anastrozole
| Evidence Level: L5 | Predicted Indications: 5 |
Table of Contents
Anastrozole: aromatase inhibitor → neuroblastoma
One-Sentence Summary
Anastrozole is a nonsteroidal aromatase inhibitor that lowers oestrogen synthesis. The TxGNN model predicts it may be relevant to neuroblastoma, but the data compiled for this report contain no clinical trials and no publications on this disease, so the prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | neuroblastoma |
| TxGNN Prediction Score | 0.9953 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Anastrozole is known as a nonsteroidal aromatase inhibitor, which reduces oestrogen production.
No link between aromatase inhibition and neuroblastoma biology (for example MYCN amplification, ALK signalling or the neural crest origin of the tumour) is established in the data compiled for this report. The high TxGNN score (0.9953) is a computational prediction only. At this stage, no mechanistic rationale for neuroblastoma can be confirmed, and any hormone-pathway hypothesis would be speculative.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for neuroblastoma.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 13858J | APO-Anastrozole | Tablet 1 mg | Not recorded in the local data |
The licence is a single-ingredient product and is currently valid. The oral tablet is the only route available locally.
Cytotoxicity
Anastrozole is a hormonal (endocrine) agent rather than a conventional cytotoxic chemotherapy. Please refer to the Product Information (PI) warnings and precautions.
Safety Considerations
- Drug Interactions: The interaction screen returned 100 records, all with an unclassified severity level. Examples include bupropion, pantoprazole, glimepiride, morphine, metformin, omeprazole, rosiglitazone, simvastatin, prednisone and acetylsalicylic acid. The clinical significance of each has not been graded and should be checked against the PI.
Please refer to the TGA-approved Product Information (PI) for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for neuroblastoma is supported only by a high model score (0.9953). There are no clinical trials or publications on this disease, and no mechanistic link is established.
To proceed, the following is needed:
- Mechanism of action data for anastrozole and any preclinical evidence linking aromatase or oestrogen signalling to neuroblastoma
- Published or registered studies that directly address neuroblastoma
- Warnings and contraindications from the TGA-approved PI
- Assessment of route and formulation suitability (including paediatric use) for the target population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.